Search results for " METASTATIC MELANOMA"

showing 4 items of 4 documents

AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression

2016

Accumulating evidences have shown the association between aberrantly expressed microRNAs (miRs) and cancer, where these small regulatory RNAs appear to dictate the cell fate by regulating all the main biological processes. We demonstrated the responsibility of the circuitry connecting the oncomiR-221&222 with the tumor suppressors miR-126&126∗ in melanoma development and progression. According to the inverse correlation between endogenous miR-221&222 and miR-126&126∗, respectively increasing or decreasing with malignancy, their enforced expression or silencing was sufficient for a reciprocal regulation. In line with the opposite roles of these miRs, protein analyses confirmed the reverse ex…

0301 basic medicineCancer ResearchCellular differentiationSettore MED/08 - Anatomia Patologicagrowth-factorCell fate determinationBiologyFatty Acid-Binding ProteinsBioinformaticsap-2 transcription factorlaw.inventioncutaneous melanoma03 medical and health sciencesMolecular Biology; Cancer Research; Genetics0302 clinical medicinelawTranscription (biology)Cell Line TumormicroRNAGeneticsmedicineHumansGene silencingMelanomaMolecular BiologyPsychological repressionsquamous-cell carcinoma; ap-2 transcription factor; cutaneous melanoma; growth-factor; metastatic melanoma; terminal fragment; cancer-cells; tumor-growth; mir-126; methylationMelanomaCell Differentiationsquamous-cell carcinomatumor-growthmedicine.diseaseMicroRNAscancer-cells030104 developmental biologyterminal fragmentmir-126030220 oncology & carcinogenesisDisease ProgressionCancer researchSuppressorOriginal Articlemethylationmetastatic melanomaOncogene
researchProduct

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients?

2019

e14035 Background: The immune response to melanoma has been shown to be locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk (infiltrating the entire base of the invasive tumor), non-brisk (infiltrating only focally) and absent. Several studies showed that greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and a higher survival rate. Since recent studies revealed an association between PD-1/PD-L1 expression levels and tumor response, the aim of our study was to investigate the correlation between plasma PD-1 and presence/absence/class of TILs in metastatic melanoma patients. Methods: The plasm…

Cancer ResearchMetastatic melanomaTumor-infiltrating lymphocytesbusiness.industryMelanomahemic and immune systemschemical and pharmacologic phenomenamedicine.disease03 medical and health sciences0302 clinical medicineImmune systemOncology030220 oncology & carcinogenesisCancer researchmedicineplasma PD-1 tumor-infiltrating lymphocytes metastatic melanomabusiness030215 immunologyJournal of Clinical Oncology
researchProduct

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

2012

T lymphocytes are often induced naturally in melanoma patients and infiltrate tumors. Given that gamma delta T cells mediate antigen-specific killing of tumor cells, we studied the representation and the in vitro cytokine production and cytotoxic activity of tumor infiltrating gamma delta T cells from 74 patients with primary melanoma. We found that gamma delta T cells represent the major lymphocyte population infiltrating melanoma, and both V delta 1(+) and V delta 2(+) cells are involved. The majority of melanoma-infiltrating gamma delta cells showed effector memory and terminally-differentiated phenotypes and, accordingly, polyclonal gamma delta T cell lines obtained from tumor-infiltrat…

MelanomasCytotoxicity ImmunologicMaleRENAL-CELL CARCINOMA OVERCOMING IMMUNOLOGICAL-TOLERANCE METASTATIC MELANOMA TUMOR-CELLS PHASE-I MEVALONATE PATHWAY TARGETING CTLA-4 LYMPH-NODES IMMUNOTHERAPY CANCERAnatomy and PhysiologySkin NeoplasmsTUMOR-CELLSLymphocytemedicine.medical_treatmentT-LymphocytesSettore MED/19 - Chirurgia PlasticaTARGETING CTLA-4Interleukin 21T-Lymphocyte SubsetsImmune PhysiologyMETASTATIC MELANOMACytotoxic T cellIL-2 receptorSkin TumorsMelanomaOVERCOMING IMMUNOLOGICAL-TOLERANCEAged 80 and overMultidisciplinaryT CellsMelanomaMalignant MelanomaQRReceptors Antigen T-Cell gamma-deltaMiddle AgedCANCERPHASE-Imedicine.anatomical_structureCytokinePhenotypeOncologyCytokinesMedicineFemaleResearch ArticleTumor ImmunologyAdultScienceT cellImmune CellsImmunologyMalignant Skin NeoplasmsDermatologyBiologyImmunophenotypingImmune systemLymphocytes Tumor-InfiltratingmedicineHumansIMMUNOTHERAPYBiologyAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleLYMPH-NODESCancers and NeoplasmsImmunologic Subspecialtiesmedicine.diseaseImmune SystemImmunologyOVERCOMING IMMUNOLOGICAL-TOLERANCE; METASTATIC MELANOMA; TUMOR-CELLS; PHASE-I; MEVALONATE PATHWAY; TARGETING CTLA-4; LYMPH-NODES; IMMUNOTHERAPY; CANCERClinical ImmunologyImmunologic MemoryMEVALONATE PATHWAYPLoS ONE
researchProduct

The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergr…

2022

Abstract Background: The management of melanoma patients with metastatic sentinel nodes (SN) is evolving based on the results of trials questioning the impact of completion lymph node dissection (CLND) and demonstrating the efficacy of new adjuvant treatments. In this landscape, new prognostic tools for fine risk stratification are eagerly sought to optimize the therapeutic path of these patients. Methods: A retrospective cohort of 2,086 patients treated with CLND after a positive SN biopsy in thirteen Italian Melanoma Centers was reviewed. Overall survival (OS) was the outcome of interest; included independent variables were the following: age, gender, primary melanoma site, Breslow thickn…

OncologyMaleTreatment of cutaneous melanomamedicine.medical_specialtyCompletion lymph node dissectionSkin NeoplasmsCLND; Completion lymph node dissection; Melanoma; Metastatic melanoma in the sentinel nodes; Nomogram; Overall survival; Prognostic factors; Risk stratification; Treatment of cutaneous melanoma; Tumor burden; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Prognosis; Retrospective Studies; Sentinel Lymph Node Biopsy; Tumor Burden; Lymphadenopathy; Melanoma; Sentinel Lymph Node; Skin NeoplasmsTumor burdenSettore MED/19 - Chirurgia PlasticaLymphadenopathyPrognostic factorsNomogramInternal medicineBiopsymedicineMetastatic melanoma in the sentinel nodesHumansCLNDOverall survivalMelanomaCLND; Completion lymph node dissection; Melanoma; Metastatic melanoma in the sentinel nodes; Nomogram; Overall survival; Prognostic factors; Risk stratification; Treatment of cutaneous melanoma; Tumor burdenRisk stratificationRetrospective Studiesmedicine.diagnostic_testbusiness.industrySentinel Lymph Node BiopsyMelanomaTumor burdenSentinel nodemedicine.diseasePrognosisLymphatic MetastasisLymph Node ExcisionSentinel Lymph Nodebusiness
researchProduct